» Articles » PMID: 39703608

The Intestine in Acute and Long COVID: Pathophysiological Insights and Key Lessons

Overview
Journal Yale J Biol Med
Specialty Biology
Date 2024 Dec 20
PMID 39703608
Authors
Affiliations
Soon will be listed here.
Abstract

Post-Acute Sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID, represents a significant and complex health challenge with a wide range of symptoms affecting multiple organ systems. This review examines the emerging evidence suggesting a critical role of the gut and gut-brain axis in the pathophysiology of Long COVID. It explores how changes in the gut microbiome, disruption of gut barrier integrity, and the persistence of SARS-CoV-2 antigens within the gastrointestinal tract may contribute to the prolonged and varied symptoms seen in Long COVID, including chronic inflammation and neuropsychiatric disturbances. The review also summarizes key insights gained about Long COVID, highlighting its multifactorial nature, which involves immune dysregulation, microvascular damage, and autonomic nervous system dysfunction, with the gut playing a central role in these processes. While progress has been made in understanding these mechanisms, current evidence remains inconclusive. The challenges of establishing causality, standardizing research methodologies, and addressing individual variations in the microbiome are discussed, emphasizing the need for further longitudinal studies and more comprehensive approaches to enhance our understanding of these complex interactions. This review underscores the importance of personalized approaches in developing effective diagnostic and therapeutic strategies for Long COVID, while also acknowledging the significant gaps in our current understanding. Future research should aim to further unravel the complex interplay between the gut and Long COVID, ultimately improving outcomes for those affected by this condition.

References
1.
Belkaid Y, Hand T . Role of the microbiota in immunity and inflammation. Cell. 2014; 157(1):121-41. PMC: 4056765. DOI: 10.1016/j.cell.2014.03.011. View

2.
Davis H, Assaf G, McCorkell L, Wei H, Low R, Reem Y . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021; 38:101019. PMC: 8280690. DOI: 10.1016/j.eclinm.2021.101019. View

3.
Rus C, de Vries B, de Vries I, Nutma I, Kooij J . Treatment of 95 post-Covid patients with SSRIs. Sci Rep. 2023; 13(1):18599. PMC: 10622561. DOI: 10.1038/s41598-023-45072-9. View

4.
Sohail A, Ahmad Cheema H, Mithani M, Shahid A, Nawaz A, Hermis A . Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis. Front Nutr. 2023; 10:1274122. PMC: 10641770. DOI: 10.3389/fnut.2023.1274122. View

5.
Zuo W, He D, Liang C, Du S, Hua Z, Nie Q . The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. Lancet Infect Dis. 2024; 24(8):845-855. DOI: 10.1016/S1473-3099(24)00171-3. View